Experience Investment Corp. (EIC) was a special purpose acquisition company (SPAC), meaning it raised money in an IPO and later asked shareholders to vote on a merger—in this case, combining with Blade Urban Air Mobility Inc. (now Strata Critical Medical Inc.). A defining feature of SPACs is the shareholder “redemption” right: before the merger closes, public investors can typically redeem their shares for roughly the cash held in trust (often about $10 per share plus interest) instead of staying invested in the post-merger company. Because that choice is made based largely on the SPAC’s proxy statement and related solicitation materials, the completeness and accuracy of those disclosures are central to how the market is supposed to work. The lawsuit was filed because shareholders alleged EIC’s sponsor and certain former directors and officers did not provide all material information needed for investors to make an informed redemption decision in connection with the Blade merger, claiming the proxy materials contained misleading statements and omissions. According to the allegations, investors who did not redeem were harmed when the post-merger shares later traded down, implying they held at prices inflated by inadequate disclosure; the $17.75 million settlement is significant because it compensates a defined group of non-redeeming holders while reinforcing that SPAC gatekeepers can face substantial liability exposure tied specifically to the redemption-vote information environment. More broadly, the case fits into a wave of SPAC-related shareholder litigation that has focused less on traditional “buy/sell” misstatements and more on whether merger-vote and redemption disclosures met securities-law standards. It also sits alongside heightened regulatory scrutiny of SPAC projections, conflicts, and de‑SPAC disclosures, including SEC rules finalized in 2024 that align key aspects of de‑SPAC disclosure and liability more closely with traditional IPO expectations—raising the stakes for sponsors and boards to ensure proxy statements fully and fairly describe the deal, risks, and incentives when investors are deciding whether to redeem or remain invested.